[go: up one dir, main page]

DK1123120T3 - Medicinsk aerosolformulering - Google Patents

Medicinsk aerosolformulering

Info

Publication number
DK1123120T3
DK1123120T3 DK99946974T DK99946974T DK1123120T3 DK 1123120 T3 DK1123120 T3 DK 1123120T3 DK 99946974 T DK99946974 T DK 99946974T DK 99946974 T DK99946974 T DK 99946974T DK 1123120 T3 DK1123120 T3 DK 1123120T3
Authority
DK
Denmark
Prior art keywords
aerosol formulation
medical aerosol
amino acid
medicinal aerosol
medical
Prior art date
Application number
DK99946974T
Other languages
Danish (da)
English (en)
Inventor
Akwete Adjei
Anthony J Cutie
Original Assignee
Aeropharm Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22567809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1123120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aeropharm Technology Inc filed Critical Aeropharm Technology Inc
Application granted granted Critical
Publication of DK1123120T3 publication Critical patent/DK1123120T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99946974T 1998-09-22 1999-09-17 Medicinsk aerosolformulering DK1123120T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09158369 US6136294C1 (en) 1998-09-22 1998-09-22 Amino acid stabilized medical aerosol formulation

Publications (1)

Publication Number Publication Date
DK1123120T3 true DK1123120T3 (da) 2006-10-02

Family

ID=22567809

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99946974T DK1123120T3 (da) 1998-09-22 1999-09-17 Medicinsk aerosolformulering

Country Status (14)

Country Link
US (1) US6136294C1 (es)
EP (2) EP1123120B1 (es)
JP (1) JP2002526459A (es)
CN (1) CN100337614C (es)
AT (2) ATE336268T1 (es)
AU (1) AU745554B2 (es)
CA (1) CA2344816C (es)
CY (1) CY1105538T1 (es)
DE (2) DE69943360D1 (es)
DK (1) DK1123120T3 (es)
ES (1) ES2267288T3 (es)
MX (1) MXPA01002894A (es)
PT (1) PT1123120E (es)
WO (1) WO2000016814A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6362225B1 (en) * 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
JP2003524646A (ja) * 2000-01-25 2003-08-19 エアロファーム テクノロジー インコーポレイテッド 医薬エアゾール製剤
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US6610272B1 (en) 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) * 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
CN1213732C (zh) * 2000-05-22 2005-08-10 奇斯药制品公司 用于加压计量吸入器的稳定药用溶液制剂
WO2002007672A2 (en) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
CZ304043B6 (cs) * 2000-08-05 2013-09-04 Glaxo Group Limited Estery steroidních thiokyselin
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6406681B1 (en) * 2000-08-21 2002-06-18 Aeropharm Technology, Inc. Method of treating a systemic disease
US6485707B2 (en) * 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6551578B2 (en) * 2001-02-15 2003-04-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6475468B2 (en) * 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7291608B2 (en) * 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
ES2307751T3 (es) * 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
WO2003028653A2 (en) * 2001-10-03 2003-04-10 Glaxo Group Limited Sustained release pharmaceutical compositions
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
CA2470498A1 (en) * 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
JP4959919B2 (ja) * 2001-12-21 2012-06-27 スリーエム イノベイティブ プロパティズ カンパニー 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物
AU2002361850A1 (en) * 2001-12-21 2003-07-30 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
WO2003070194A2 (en) * 2002-02-20 2003-08-28 Sepracor Inc. Amino acid and peptide-modified forms of glucocorticoids
EP1480691A4 (en) * 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20050203217A1 (en) * 2002-04-30 2005-09-15 Pomrink Gregory J. Stabilizers for polymerizable biocompatible materials
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
US8278355B2 (en) 2006-09-12 2012-10-02 Therexcell Pharma Inc. Isovaline for treatment of pain
GB0620700D0 (en) * 2006-10-19 2006-11-29 3M Innovative Properties Co Metered dose valves and dispensers
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201118188D0 (en) 2011-10-21 2011-12-07 3M Innovative Properties Co Manufacture of medicinal aerosol canisters
GB201210580D0 (en) 2012-06-14 2012-08-01 3M Innovative Properties Co Metered dose dispensing valve
GB201221063D0 (en) 2012-11-23 2013-01-09 3M Innovative Properties Co Metered dose dispensing valve
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
CN106137965A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有环索奈德的气雾剂药物组合物
CN106138014A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有糖皮质激素的气雾剂药物组合物
CN106137964A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有丙酸倍氯米松的气雾剂药物组合物
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN110302157B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种异丙托溴铵气雾剂组合物及其制备方法
CN110302184B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 赖氨酸在季铵盐类m受体拮抗剂气雾剂中的应用
CN110302158B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种噻托溴铵气雾剂组合物及其制备方法
CN110742875B (zh) * 2018-07-05 2022-09-30 北京盈科瑞创新药物研究有限公司 一种吸入用吡非尼酮溶液制剂及其制备方法和应用
CN110755414A (zh) * 2019-11-12 2020-02-07 南京华盖制药有限公司 一种酒石酸阿福特罗气雾剂及其制备方法
GB2614901A (en) * 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (es) * 1956-03-21 1900-01-01
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3261748A (en) * 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) * 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
FI913899A7 (fi) * 1989-02-23 1991-08-19 Rorer Int Holdings Inc Terapeuttiset aerosoliseokset
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
HUT67449A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2,3,3,3-heptafluoropropane
NZ244439A (en) * 1991-09-25 1994-01-26 Fisons Plc Pressurised aerosol compositions comprising hydrofluoroalkane, dispersed
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
GB9202522D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
DE69413955T2 (de) * 1993-03-17 1999-04-01 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
DK0731688T3 (da) * 1993-12-02 2003-06-23 Abbott Lab Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
CN1069192C (zh) * 1994-04-21 2001-08-08 王世立 一种气溶胶制剂及其配制方法
JP4155594B2 (ja) * 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
ATE287703T1 (de) * 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit

Also Published As

Publication number Publication date
ATE336268T1 (de) 2006-09-15
DE69932835T2 (de) 2007-02-01
AU745554B2 (en) 2002-03-21
MXPA01002894A (es) 2002-06-04
US6136294A (en) 2000-10-24
PT1123120E (pt) 2006-10-31
DE69932835D1 (de) 2006-09-28
EP1123120A1 (en) 2001-08-16
CY1105538T1 (el) 2010-07-28
EP1123120A4 (en) 2003-07-23
ES2267288T3 (es) 2007-03-01
DE69943360D1 (de) 2011-05-26
EP1123120B1 (en) 2006-08-16
AU5926799A (en) 2000-04-10
EP1731140A3 (en) 2007-06-27
CA2344816C (en) 2011-05-24
CN100337614C (zh) 2007-09-19
HK1041835A1 (zh) 2002-07-26
CN1328473A (zh) 2001-12-26
EP1731140B1 (en) 2011-04-13
CA2344816A1 (en) 2000-03-30
HK1097777A1 (en) 2007-07-06
EP1731140A2 (en) 2006-12-13
JP2002526459A (ja) 2002-08-20
ATE505184T1 (de) 2011-04-15
US6136294C1 (en) 2002-09-24
WO2000016814A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
US6136294C1 (en) Amino acid stabilized medical aerosol formulation
MXPA03000442A (es) Una formulacion medicinal en aerosol.
EP1135173A4 (en) MEDICINAL AEROSOL FORMULATION
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
DK0656207T4 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
DE60019167D1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
CY1109212T1 (el) Φαρμακευτικες συνθεσεις για την θεραπεια του ασθμα
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
UA70921C2 (uk) Похідні 2-(імінометил)амінофенілу, спосіб їх одержання (варіанти) та фармацевтична композиція, що містить ці сполуки
MXPA05002337A (es) Formulacion medicinal en aerosol, estabilizada con agua.
GB0016876D0 (en) Novel formulation
WO1998008517A3 (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
WO2002007672A3 (en) A medicinal aerosol formulation
EP1523976A3 (en) Pharmaceutical formulations of salmeterol
MX9707238A (es) Formulaciones en aerosol de butixocort.